{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:58:24Z","timestamp":1774403904226,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate the effects of SARS-CoV-2 infection, as well as short- (within 48 hours) and long-term (within 30 days) adverse events (AEs) of SARS-CoV-2 vaccines, including arthritis flares in a large cohort of patients with inflammatory arthritis (IA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study comprising 362 patients: 94 (26%) rheumatoid arthritis, 158 (43.6%) psoriatic arthritis and 110 (30.4%) ankylosing spondylitis; and 165 healthy controls (HC) to ascertain the prevalence and severity of SARS-CoV-2 infection in patients with IA, the rate of AEs associated with SARS-CoV-2 vaccines and disease flares within a month of the vaccination. All patients provided informed consent and data about SARS-CoV-2 infection and\/or vaccination status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One-hundred-seventeen (32.3%) patients and 39 (23.6%) HC were affected by SARS-CoV-2 infection. Forty (34.2%) patients experienced an IA flare within one month of infection, of whom 3 (7.5%) needed to switch therapy. The prevalence of SARS-CoV-2 infection, disease severity, and hospitalization rate were not significantly different. At least one shot of SARS-CoV-2 vaccine was administered in 331 (91.4%) patients and 147 (89.1%) HC. Within 48 hours, 102 (30.8%) patients developed vaccine-related AEs; 52 (15.7%) patients with &amp;gt;1 vaccine dose experienced an IA flare-up, of whom 12 (23.1%) needed to switch therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A significantly higher rate of IA flare was observed among patients who contracted SARS-CoV-2 infection vs. those without infection. Patients with IA experienced flares after SARS-CoV-2 vaccination, though it was not statistically significant.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1207015","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T11:06:56Z","timestamp":1690369616000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of SARS-CoV-2 infection and vaccination on inflammatory arthritis: a cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Giovanni","family":"Striani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagrazia","family":"Lorenzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Scagnellato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Vangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Frizzera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierino","family":"De Sandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa363","article-title":"Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China","volume":"222","author":"Chi","year":"2020","journal-title":"J Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42358-021-00204-5","article-title":"Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders","volume":"61","author":"Ruscitti","year":"2021","journal-title":"Adv Rheumatol Lond Engl"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211012","article-title":"COVID-19 hospitalizations, intensive care unit stays, ventilation, and death among patients with immune-mediated inflammatory diseases compared to controls","volume":"49","author":"Eder","year":"2022","journal-title":"J Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001464","article-title":"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"7","author":"Hasseli","year":"2021","journal-title":"RMD Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ijid.2020.07.076","article-title":"Does gender influence clinical expression and disease outcomes in COVID-19? a systematic review and meta-analysis","volume":"99","author":"Ortolan","year":"2020","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06040-9","article-title":"Posterior reversible encephalopathy syndrome: an atypical neurological manifestation of SARS-CoV-2 infection","volume":"43","author":"Gasparotto","year":"2022","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210742","article-title":"The interplay between COVID-19 and spondyloarthritis or its treatment","volume":"49","author":"Rosenbaum","year":"2022","journal-title":"J Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/1573397119666230116151541","article-title":"Covid 19 in patients with systemic inflammatory diseases: impact on disease activity","volume":"19","author":"Miledi","year":"2023","journal-title":"Curr Rheumatol Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42358-022-00268-x","article-title":"COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-brasil cross-sectional data","volume":"62","author":"Marques","year":"2022","journal-title":"Adv Rheumatol Lond Engl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682850","article-title":"SARS-CoV-2 infection in spondyloarthritis patients treated with biotechnological drugs: a study on serology","volume":"12","author":"Ortolan","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24831","article-title":"Increased risk of COVID-19 in patients with rheumatoid arthritis: a general population-based cohort study","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Care Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25028","article-title":"Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: a general population study","volume":"75","author":"Li","year":"2022","journal-title":"Arthritis Care Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24837","article-title":"Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease","volume":"74","author":"Dharia","year":"2022","journal-title":"Arthritis Care Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24611","article-title":"Changes in disease-modifying antirheumatic drug treatment for patients with rheumatoid arthritis in the US during the COVID-19 pandemic: a three-month observational study","volume":"73","author":"Michaud","year":"2021","journal-title":"Arthritis Care Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13075-021-02674-w","article-title":"Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine","volume":"24","author":"Spinelli","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/ldv88a","article-title":"COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis","volume":"41","author":"Vacchi","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac224","article-title":"Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey","volume":"61","author":"Pengo","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"B20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/vaccines9070730","article-title":"Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a two-centers study","volume":"9","author":"Rotondo","year":"2021","journal-title":"Vaccines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05039-3","article-title":"COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study","volume":"42","author":"Fragoulis","year":"2022","journal-title":"Rheumatol Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac249","article-title":"Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey","volume":"61","author":"Rider","year":"2022","journal-title":"Rheumatol Oxf Engl"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210863","article-title":"Safety profile and low risk of disease relapse after BNT162b2 mRNA SARS-CoV-2 vaccination in patients with rare rheumatic diseases","volume":"49","author":"Fornaro","year":"2022","journal-title":"J Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001814","article-title":"Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey","volume":"7","author":"Sattui","year":"2021","journal-title":"RMD Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220732","article-title":"Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in new York city","volume":"80","author":"Barbhaiya","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/vx44zn","article-title":"New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort","volume":"41","author":"Gasparotto","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/jpm11121283","article-title":"COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases","volume":"11","author":"Pinte","year":"2021","journal-title":"J Pers Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update","volume":"81","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. a proposal for modification of the new York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American college of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B35","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheumatol"},{"key":"B37","volume-title":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification","year":"2018"},{"key":"B38","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/diagnostics11060955","article-title":"COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis","volume":"11","author":"Pomara","year":"2021","journal-title":"Diagn Basel Switz"},{"key":"B39","unstructured":"Clinical spectrum of SARS-CoV-2 infection"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 transmission and pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001461corr1","article-title":"High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV brasil registry","volume":"7","author":"Cdl","year":"2021","journal-title":"RMD Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1207015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T11:07:04Z","timestamp":1690369624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1207015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2023.1207015"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1207015","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"article-number":"1207015"}}